Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Deffered Revenue (2016 - 2017)

Aytu Biopharma (AYTU) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $1451.0 as the latest value for Q2 2017.

  • Quarterly Non-Current Deffered Revenue fell 82.34% to $1451.0 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $1451.0 through Jun 2017, down 82.34% year-over-year, with the annual reading at $1451.0 for FY2017, 82.34% down from the prior year.
  • Non-Current Deffered Revenue for Q2 2017 was $1451.0 at Aytu Biopharma, down from $3119.0 in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $425893.0 in Q2 2015, with the low at $1451.0 in Q2 2017.
  • Average Non-Current Deffered Revenue over 3 years is $97565.3, with a median of $8215.0 recorded in 2016.
  • Peak annual rise in Non-Current Deffered Revenue hit 59.06% in 2016, while the deepest fall reached 98.4% in 2016.
  • Over 3 years, Non-Current Deffered Revenue stood at $11694.0 in 2015, then crashed by 59.06% to $4787.0 in 2016, then plummeted by 69.69% to $1451.0 in 2017.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $1451.0, $3119.0, and $4787.0 for Q2 2017, Q1 2017, and Q4 2016 respectively.